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Abstract
Background: Rheumatoid arthritis (RA) is a multifactorial autoimmune disease, which is characterized by
inflammation of synovial joints leading to the destruction of cartilage and bone. Infiltrating mast cells can be found
within the inflamed synovial tissue, however their role in disease pathogenesis is unclear. Therefore we have
studied the role of mast cells during different phases of experimental arthritis.
Methods: We induced collagen-induced arthritis (CIA), the most frequently used animal model of arthritis, in an
inducible mast cell knock-out mouse and determined the effect of mast cell depletion on the development and
severity of arthritis.
Results: Depletion of mast cells in established arthritis did not affect clinical outcome. However, depletion of mast
cells during the preclinical phase resulted in a significant reduction in arthritis. This reduction coincided with a
decrease in circulating CD4+ T cells and inflammatory monocytes but not in the collagen-specific antibody levels. Mast
cell depletion resulted in reduced levels of IL-6 and IL-17 in serum. Furthermore, stimulation of splenocytes from mast
cell-depleted mice with collagen type II resulted in reduced levels of IL-17 and enhanced production of IL-10.
Conclusions: Here we show that mast cells contribute to the preclinical phase of CIA. Depletion of mast cells before
disease onset resulted in an altered collagen-specific T cell and cytokine response. These data may suggest that mast
cells play a role in the regulation of the adaptive immune response during the development of arthritis.
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Background
Rheumatoid arthritis (RA) is characterized by progres-
sive inflammation of the synovial joints that leads to the
breakdown of cartilage and bone, eventually resulting in
malformation of hands and feet, thereby reducing the
quality of life for the patient [1]. In the western world,
RA affects around 0.5–1 % of the general population [2].
The etiology and pathology of RA are not completely
understood and environmental and genetic factors are
thought to play a role in disease pathogenesis [3, 4].
Various types of immune cells, such as macrophages, B
cells, T cells and mast cells have been described to
contribute to the initiation and progression of joint
destruction [5]. Mast cells are potent innate immune
effector cells and accumulate in the synovium during
RA progression. Over time, mast cells can account
for up to 5 % of all nucleated cells within the inflamed
synovial tissue [6, 7]. Mast cells express a wide range of
surface receptors that allow them to be activated by differ-
ent ligands, such as immunoglobulin E (IgE), cytokines,
(endogenous) Toll-like receptor (TLR) ligands and im-
munoglobulin G (IgG) immune complexes [8]. Many of
these ligands have been detected within the inflamed
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synovial tissue of RA patients. Depending on the activa-
tion route, mast cells can release a wide range of pre-
formed mediators such as chymase, tryptase and
histamine and can also release cytokines and chemokines
[9]. The precise role of mast cells in the pathogenesis of
RA is unknown, but activation of synovial mast cells could
potentially contribute to the further progression of joint
destruction either by the recruitment of leukocytes such
as neutrophils and monocytes but could also facilitate the
breakdown of cartilage in the joint by activating osteo-
clasts via release of mediators like histamine [10, 11]. To
date several mouse studies have been conducted to study
the role of mast cells in experimental arthritis. Different
results were obtained in these studies, which could poten-
tially have been caused by the choice of mast cell-deficient
mouse strain or the method of arthritis induction [12–15].
However, most of these studies were performed in arthritis
models based on the infusion of autoreactive antibodies
such as with the K/BxN model. The pathogenesis of K/
BxN model is based on the transfer of serum containing
anti-glucose-6-phosphate (GPI) antibodies obtained from
K/BxN mice. Infused anti-GPI antibodies in recipient mice
will home to distal joints were they form immune com-
plexes, which activate an inflammatory response via com-
plement receptors, Fc receptors and is future-dependent
on production of tumor necrosis factor alpha (TNF-α)
and interleukin (IL)-1. Adaptive immune cells such as T
cells are reported not to be required for disease induction
in this model [16, 17]. Nonetheless, T cells are thought to
play a major role in RA, therefore we studied mast cells in
the collagen-induced arthritis (CIA) model where T cells
contribute significantly to the initiation of the pathogenic
immune response [18, 19]. For example, in a study con-
ducted by Jansen et al. CD4+ T cells were depleted in CIA
mice using either abatacept or a CD4+- depleting anti-
body. This depletion resulted in a significant reduction of
collagen-specific antibodies, which coincided with a lower
disease activity [20]. This study confirms the importance
of T cells in the early phases of CIA in the establishment
of a strong humoral immune response toward collagen
type II (CII). CIA has many similarities with RA, like
cartilage degradation, fibrin deposition, mononuclear
infiltration, synovial cell hyperplasia, pannus formation,
periosteal bone formation, and eventual ankyloses of
one or more joints [18]. Comparable to human RA,
CIA is composed of a preclinical (prodromal) and a
clinical phase. The preclinical phase is defined as the
period following the initial immunization with collagen
and preceding the onset of clinical symptoms, and
could be considered as a model for the prodromal stage
of RA in which the underlying autoimmune response is
already present but there is no visible manifestation of
clinical symptoms. The clinical phase of CIA is charac-
terized by an irreversible destruction of synovial joints.
Recently, it was reported that depletion of mast cells in
MCPT5-Cre-iDTR mice, before the first immunization
with collagen type II (CII), could reduce the clinical
outcome by altering the T cell subsets in the draining
lymph nodes [21].
Although the role of mast cells in the initial onset of
the pathogenic immune response is of great scientific
importance, information about mast cells in later stages
of disease might be more helpful for potential thera-
peutic intervention. Therefore the aim of this current
study is to further dissect the role of mast cells in arth-
ritis by depletion of them during these later phases of
the disease.
To this end, we made use of the red mast cell basophil
(RMB) mouse, which is a novel mast cell inducible
knock-in mouse strain based on the transgenic expres-
sion of the simian diphtheria toxin receptor (DTR). Nor-
mally, mice are resistant to diphtheria toxin (DT) but
cells who express the DTR will become highly sensitive
to DT, which will cause apoptosis after challenges with
DT. In the RMB mice, the DTR is expressed under con-
trol of the promoter from the β-chain of the high-
affinity receptor for IgE (FcεRI) [22]. In mice, mast cells
and basophils express a high-affinity receptor for IgE
(FcεRI) composed of one alpha, one beta, and two
gamma chains, which is essential for cell surface expres-
sion [23]. Although it has been reported that other im-
mune cells such as dendritic cells and monocytes can
express the FcεRI these cells lack the β-chain of the re-
ceptor [24, 25]. In summary, only basophils and mast
cells express the β-subunit, which allows a cell-specific
ablation in this current mouse model [22, 23, 26, 27]. As
reported previously, basophils are depleted only for a
short period of time (<12 days) and the depletion of
mast cells lasts at least above 6 months in the peritoneal
cavity [22]. In this study, we employed the RMB mouse
to determine the contribution of mast cells to the pre-
clinical and clinical phase of arthritis by depleting mast
cells during these stages.
Methods
Mice
All animal work was performed in accordance with
national guidelines, and experiments were approved
by the animal welfare committee of the Leiden University
Medical Centre.
The red mast cell and basophil mice (RMB or B6;
B6.Ms4a2tm1Mal mice) [22] were backcrossed for one
generation with wild-type DBA/1 mice (Harlan BV,
Horst, The Netherlands) in order to obtain mice that are
highly susceptible for collagen-induced arthritis and in
which FcεRIβ-expressing cells can be depleted by injec-
tion of DT.
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Collagen-induced arthritis and collagen antibody-induced
arthritis
Collagen-induced arthritis (CIA) was induced in 8–10-
week-old male RMB-DBA/1 mice by injection in the tail
base with 100 μg of bovine collagen type II (CII) (2 mg/
mL) (Chondrex, Inc., Redmond, WA, USA) emulsified
in complete Freund’s adjuvant (CFA) (1 mg/mL; Difco,
Detroit, MI, USA). On day 21 the mice received a sub-
cutaneous boost with 100 μg CII in incomplete Freund’s
adjuvant (IFA) (Difco) [28].
Collagen antibody-induced arthritis was induced by
intravenous injection of 1 mg anti-collagen antibodies
(Athrogen 5 Clone 2; Chondrex) intravenously on day 0
[29]. A clinical score was assigned based on a scoring
protocol in which each swollen or red phalanx was given
0.5 point and 1 point per toe. A red or swollen knuckle
was given 1 point, a red or swollen footpad was given 1
point and a swollen ankle and/or wrist were given 5
points. The maximum score for each paw was 15 points,
resulting in a maximum possible score of 60 points per
mouse. For the immunoglobulin levels, mice were bled
before immunization, on day 21, and at the end of
follow-up. Blood was centrifuged and serum was har-
vested and stored at −20 °C until use.
In vivo depletion of FcεRIβ+ cells
To systemically deplete all FcεRIβ+ cells, mice were
injected intraperitoneally (i.p.) for three times with a 1-day
interval with 1 μg diphtheria toxin (DT) (DT unnicked, C.
diphtheria (Cat # 322326), CalBiochem, San Diego, CA,
USA), (40 ng/g bodyweight).
To deplete mast cells and basophils in the clinical
phase of arthritis, mice received either DT or
phosphate-buffered saline (PBS) upon clinical manifest-
ation of arthritis. The mice were divided over two
groups with a similar clinical score at the day of injec-
tion. Mast cells and basophils were depleted in one
group by i.p. DT injection, while the control group re-
ceived i.p. injections with PBS.
To deplete mast cells in the preclinical phase of arth-
ritis, mice were injected with either DT or PBS starting
7 days after the first immunization. Efficiency of deple-
tion was measured by FACS analysis for circulating
basophils (CD49b+/FcεRI+/IgE+) 3 days after the last DT
injection. At sacrifice, mast cells in the joint were visual-
ized by staining with a napthol AS-D chloroacetate east-
erase staining kit (CEA) (Cat# 91C-1KT, Sigma-Aldrich,
Munich, Germany). For a schematic overview of the
arthritis experiment, see Additional file 1: Figure S1.
Histology
The hind legs of arthritic mice were harvested at end of
the study. Tissues were fixed in 4 % formalin and decal-
cified in PBS containing 10 % EDTA for 14 days before
embedding into paraffin. Sections were cut 5 μm thick
and either a toluene blue staining or an enzymatic stain-
ing (CEA) was performed to quantify the amount of
mast cells.
To analyze the joint inflammation, sections were stained
with hematoxylin and eosin (H&E). Histopathological
changes were scored using the following parameters; 0: no
inflammation; 1: hyperplasia of the synovial layer, infiltra-
tion of leukocytes into the joint; 2: pannus formation; 3:
destruction of cartilage; and 4: destruction of bone and
extensive infiltrates. The sample treatment protocol was
withheld from the evaluators to prevent bias.
Flow cytometry
At sacrifice, blood was obtained in EDTA tubes and
erythrocytes were removed using a specific erythrocyte
lysis buffer (0.15 M NH4Cl, 10 mM NaHCO3, 0.1 mM
EDTA, pH 7.3).
Blood leukocytes were stained extracellularly to deter-
mine (a) monocytes (NK1.1-/Ly6G-/CD11bhi), inflamma-
tory monocytes (NK1.1-/Ly6G-/CD11bhi/Ly6Chi/CCR2+),
and neutrophils (NK1.1-/Ly6Ghi/CD11bhi), (b) basophils
(CD3-/CD4-/CD19-/CD8-/CD49b+/IgE+/CD117-), (c) T
cells (CD3+/CD4+), and (d) B cells (CD19+/B220+). The
antibodies used (eBioscience, Inc., San Diego, CA, USA)
are summarized in Table 1. Flow cytometry analysis was
performed on the FACSCanto II and data were analyzed
using FACSDiva software (Becton Dickinson, Franklin
Lakes, NJ, USA).
Stimulation of splenocytes
At sacrifice, a single cell suspension was prepared from
the spleen by using a 70-μm cell strainer (Falcon, Corning,
NY, USA). Erythrocytes were removed using a specific
erythrocyte lysis buffer (0.15 M NH4Cl, 10 mM NaHCO3,
0.1 mM EDTA, pH 7.3).
Regulatory T cell numbers were determined by staining
extracellular with eFluor-450-conjugated rat anti-mouse
CD4. Next, cells were fixed and permeabilized according
to the supplier’s protocol (eBioscience). Subsequently, cells
were stained with APC-conjugated rat anti-mouse/human
FoxP3 or corresponding isotype as a control (eBioscience).
To determine inflammatory Th17 T cell phenotype in the
spleen, 400,000 splenocytes/well were cultured in 96-well
round-bottom plates (Greiner Bio-One, Frickenhausen,
The Netherlands) and stimulated with anti-CD3 and anti-
CD28 (2 μg/mL each, eBioscience) in complete IMDM,
supplemented with 10 % heat-inactivated fetal calf serum,
100 u/mL penicillin/streptomycin, 2 mM L-glutamine
(PAA Laboratories, Pasching, Austria), and 20 mM β-
mercaptoethanol (Sigma-Aldrich). After 1 hour, brefeldin
A (Sigma-Aldrich) was added up to a concentration
of 10 μg/mL to inhibit secretion of the cytokines.
After an additional 4 hours of incubation, cells were
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washed twice with FACS buffer (PBS, 1 % BSA, 2
mM EDTA) and stained for T cell surface markers.
Cells were first stained with eFluor-450-conjugated rat
anti-mouse CD4. Next, cells were fixed and permeabilized
according to the supplier’s protocol (eBioscience),
followed by intracellular staining with PE-conjugated rat
anti-mouse IL-17 or corresponding isotype as a control
(eBioscience).
For the determination of the cytokine profile, spleno-
cytes were cultured at 300,000 cells/well in triplicate and
stimulated with either αCD3/28 (2 μg/mL each) or 50
μg/mL collagen type II for 96 hours, while unstimulated
cells served as controls. Subsequently, the supernatant
was collected for cytokine analysis.
Serum immunoglobulin detection and cytokine levels
Total IgG1, IgG2a, IgG2c and IgE serum levels were
determined by enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s manual (Bethyl
Laboratories, Montgomery, TX, USA). Collagen-specific
IgG1, IgG2a, IgG2c and IgE were determined using an
in-house ELISA procedure. In short, bovine collagen was
coated overnight at a concentration of 10 μg/mL in
carbonate-bicarbonate buffer (pH9.6) on NUNC Maxisorp
plates. Plates were washed with PBS/0.05 % Tween20, and
blocked with PBS/10 % milk for 2 hours. After washing,
the plates were incubated with 1/8000 diluted serum in
PBS/1 % BSA/0.05 % Tween20 for 18 hours at 4C°. The
different Igs were detected using an horseradish peroxid-
ase (HRP)-conjugated goat anti-mouse Ig antibody
(Southern Biotec, Birmingham, AL, USA) diluted in PBS/
1 % BSA/0.05 % Tween20. HRP enzyme activity was visu-
alized using ABTS. As a standard, serial dilutions of a
pooled serum sample from mice with CIA were used.
Cytokine levels were determined using a commercially
available ELISA kit (BD: IL-6, TNF, interferon (IFN)-γ,
IL-10) and eBioscience (IL-17A). All cytokine ELISAs
were performed according to the manufacturer’s
protocol.
Statistical analysis
Data are expressed as mean ± standard error of the mean
(SEM). All data presented was tested with the Shapiro-
Wilk test for normal distribution. An unpaired two-tailed
Student’s t test was used to compare normally distributed
data between two groups of animals. Data of two groups
with more than one variable were analyzed by two-way
analysis of variance (ANOVA) followed by a Bonferroni
post hoc test.
Clinical scores of mice were compared by calculating
the area under the curve (AUC) of the clinical score
from each mouse overtime followed by an unpaired two-
tailed Student’s t test. Statistical analysis was performed
using Prism (Graphpad Software, Inc., San Diego, CA,
USA). Probability values of p < 0.05 were considered
significant.
Results
FcεRIβ+ cell depletion in established arthritis does not
reduce clinical score or delay disease progression
Arthritis is characterized by a constant activation and re-
cruitment of immune cells into the joint leading to the
destruction of cartilage and bone. Mast cells accumulate
in the inflamed joint and could therefore actively con-
tribute to the disease progression in CIA. To investigate
the contribution of mast cells to the progression of
established CIA in RMB-DBA/1 mice, FcεRIβ+ cells were
depleted in the effector phase of the disease (Additional
file 1: Figure S1a.). As shown in Fig. 1a, depletion of
FcεRIβ+ cells after clinical manifestation of CIA had no
effect on the clinical score. In both groups, we detected
similar levels of specific immunoglobulins toward colla-
gen type II (CII) in serum (Fig. 1b). Mast cells were
present in the joints of saline-treated mice, whereas mast
cell were completely absent in DT-treated mice (Fig. 1c).
Further analysis of the different blood leukocyte popula-
tions by flow cytometry showed no differences in per-
centages of basophils, neutrophils, (inflammatory)
monocytes, CD4+ T cells, and B cells (Fig. 1d). Taken to-
gether, these data indicate that depletion of FcεRI+ cells
after the onset of CIA did not affect progression of CIA.
To further study the role of mast cells in the effector
phase of arthritis we used the collagen antibody-induced
arthritis (CAIA) model in RMB-DBA/1 mice [29]. Un-
like the CIA model, this model does not require an ac-
tive adaptive immune response toward collagen type II.
Table 1 Antibody panels used for flow cytometry
Staining FITC PE PerCP APC e-Fluor-450
A NK1.1
(Clone: PK136)
Ly6G
(Clone: 1A8)
Ly6C
(Clone: HK1.4)
CCR2
(Clone: 475301)
CD11b
(Clone: M1/70)
B IgE
(Clone: R35-72)
CD117
(Clone: 2B8)
CD3/4/19/8
(dump channel)
CD49b
(Clone: HMa2)
n/a
C CD44
(Clone: IM7)
CCR7
(Clone: 4B12)
CD8α
(Clone: 53-6.7)
CD62L
(Clone: MEL-14)
CD4
(Clone: GK1.5)
D IgM
(Clone: II/41)
CD45RA
(Clone: RA3-6B2)
CD19
(Clone: eBio1D3)
IgD
(Clone: 11-26c)
CD5
(Clone: 53-7.3)
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The CAIA model depends on the injected pathogenic
anti-collagen antibodies and resembles the effector phase
of collagen-induced arthritis after the adaptive immune
response has developed. Mast cell-deficient or -compe-
tent RMB-DBA/1 mice were intravenously (i.v.) injected
with anti-collagen antibodies and scored daily for arth-
ritis development (Additional file 1: Figure S1b). We did
not observe a significant difference in clinical score be-
tween both groups (Fig. 2a). At sacrifice, a total mast cell
depletion was confirmed in the joints of DT-treated
mice (Fig. 2b). Flow cytometry analysis of the blood
compartment showed no significant differences in blood
leukocytes subsets (basophils, neutrophils, monocytes,
inflammatory monocytes, T cells, and B cells) as depicted
in Fig. 2c. These findings suggest that mast cells do not
play a role in experimental arthritis once arthritis has
fully developed and the anti-collagen type II antibody
response has been developed.
Fig. 1 Depletion of FcεRIβ+-cells in clinical phase of CIA does not influence clinical outcome in RMB-DBA/1 mice. a Progression of CIA was monitored
by clinical scoring of RMB-DBA/1 mice injected with either PBS or DT (n = 15/group). b Serum levels of IgG1, IgG2a, IgG2c and IgE isotype antibodies
directed against collagen type II were quantified in serum from PBS- or DT-injected RMB-DBA/1 mice (n = 15/group). c Mast cell numbers were
determined in ankle joints of PBS- and DT-treated mice (n = 15/group). Arrows show mast cells in the joint. d FACS analysis for common peripheral
leucocytes in both groups (***p< 0.001) A representative example of two independent experiments is depicted. DT diphtheria toxin, IgE immunoglobulin
E, IgG immunoglobulin G, PBS phosphate-buffered saline
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Absence of mast cells in the preclinical phase of CIA
reduces clinical outcome
Mast cells can secrete various mediators that can regu-
late the immune response. Therefore mast cells could
potentially influence the clinical course of arthritis by
regulating collagen-specific B and T cell response re-
quired for the development of disease. The CII-specific
response starts to develop directly after the first
immunization, but mice typically do not develop arthritis
until after the booster injection 3 weeks later. To investi-
gate whether mast cells can play an immunoregulatory
role during this phase of disease, we depleted FcεRIβ+ cells
in RMB-DBA/1 mice 7 days after the first immunization
as schematically shown in Additional file 1: Figure S1c.
Absence of FcεRIβ+ cells in the preclinical phase of
CIA resulted in significantly lower clinical score (AUC:
PBS 246 ± 16 vs. DT 183 ± 15, p = 0.0085) (Fig. 3a). De-
pletion of FcεRIβ+ cells did not affect anti-collagen type
II antibody titers (Fig. 3b). Histological analysis showed
a complete depletion of mast cells in the joints of DT-
treated mice (Fig. 3c), whereas in PBS-treated mice mast
cells were present in the affected joints. Further analysis
of the joint inflammation in both groups showed a sig-
nificant reduction in histological score in FcεRIβ+ cell-
Fig. 2 Clinical outcome of collagen antibody-induced arthritis (CAIA) is independent of FcεRIβ+-cells. a Progression of CAIA-induced arthritis in
both mast cell-competent and -depleted RMB-DBA/1 mice. (n = 6/group) (b) Mast cell numbers in the ankle joint of PBS- and DT-injected
RMB-DBA/1 mice. (n = 6/group) (c) FACS analysis for common peripheral leukocytes in both groups (n = 6/group). AUC area under the
curve, DT diphtheria toxin, PBS phosphate-buffered saline
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depleted mice (Fig. 3d). At the end of follow-up (day
45), we detected reduced serum levels of the inflamma-
tory cytokines IL-6 (PBS 510 ± 52 vs. DT 339 ± 46 pg/
mL, p = 0.02) and IL-17 (PBS 521 ± 75 vs. DT 326 ± 50
pg/mL, p = 0.04) and elevated anti-inflammatory IL-10
(PBS 158 ± 9 vs. DT 212 ± 18 pg/mL, p = 0.02) in the
serum of FcεRIβ+ cell-depleted mice compared to
FcεRIβ+ cell-competent mice (Fig. 4a). We did not ob-
serve any differences of TNF-α levels in the serum
(Fig. 4a) and expression levels of TNF-α within the in-
guinal lymph node (data not shown). We performed
flow cytometry analysis on the blood compartment for
circulating basophils, monocytes, neutrophils, T cells,
and B cells. Since the mice received the last DT injection
more than 12 days before sacrifice, we detected a
complete repopulation of basophils in DT-treated mice
(Fig. 4b). Peripheral blood neutrophil and total mono-
cytes (Fig. 4b) were not different between groups. None-
theless we did observe a reduction of inflammatory
monocytes (CD11b+/Ly6G-/Ly6Chi/CCR2+) in FcεRIβ+
cell-depleted mice (Fig. 4b). Furthermore, CD4+ T cells
in FcεRIβ+ cell-depleted mice was decreased by 22 %
(Fig. 4b), while the percentage of CD8+ T cells (Fig. 4b)
and B cells (Fig. 4b) was not affected.
To further investigate the phenotype of the circulating
CD4 T cells, we stimulated splenocytes with α-CD3/28,
followed by intracellular flow cytometry staining for dif-
ferent T cell subsets. The balance between Th17 and
regulatory T cells is thought to influence arthritis sever-
ity in mice [30, 31]. As shown in Fig. 5a, b depletion of
FcεRIβ+ cells influenced T cell cytokine production, as
it resulted in decreased IL-17-producing T cells (PBS
1.02 ± 0.15 vs. DT 0.67 ± 0.04 %, p = 0.02) and an in-
crease in FoxP3+regulatory T cells (PBS 6.50 ± 0.27 vs.
DT 7.80 ± 0.34 %, p = 0.01) (Fig. 5a, b) compared to
nondepleted mice. To study the antigen-specific re-
sponse toward collagen type II, splenocytes were stim-
ulated with CII and cytokine production was analyzed
by ELISA. Mast cell depletion resulted in an increase
in collagen-specific IL-10 production (PBS 875 ± 225
Fig. 3 Absence of FcεRIβ+ cells during preclinical phase of CIA reduces clinical outcome of arthritis in effector phase of disease. a Progression of
CIA was monitored by clinical scoring of RMB-DBA/1 mice, which have been injected with either PBS or DT in the preclinical phase of
CIA (n = 15/group). b Serum levels of IgG1, IgG2a, IgG2c and IgE isotype antibodies directed against collagen type II were quantified in
serum from PBS- or DT-injected RMB-DBA/1 mice (n = 15/group) (c) Mast cell numbers were determined in ankle joints of PBS- and DT-treated mice
(n = 6/group). Arrows show mast cells in the joint. d Histological score of joint inflammation in the ankle joint of PBS- and DT-treated mice (n = 15/
group). Representative H&E-stained sections of ankles obtained from PBS- and DT-treated RMB-DBA/1 mice. *p < 0.05. A representative example of two
independent experiments is depicted. AUC area under the curve, DT diphtheria toxin, IgE immunoglobulin E, IgG immunoglobulin G, PBS
phosphate-buffered saline
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vs. DT 1912 ± 96 pg/mL, p = 0.002) and a decrease in
collagen-specific IL-17 production (PBS 301 ± 73 vs.
DT 121 ± 33 pg/mL, p = 0.03) (Fig. 5c). This change
in the T cell cytokine response was in line with the
intracellular cytokine staining results for the CD4+ T
cells.
As DT injections can lead to side effects, we per-
formed additional control experiments in which wild-
type mice (C57Bl/6-DBA/1) were treated with either
PBS or DT in a similar experimental setup as described
in Additional file 1: Figure S1c. We did not observe any
effects of DT on clinical score (Additional file 2: Figure
S2a), serum cytokine profile (Additional file 2: Figure
S2b), and blood leukocyte subsets (Additional file 2:
Figure S2c) in wild-type control mice. A specific stimula-
tion of splenocytes resulted in an increase in IL-17 and
TNF, but no differences in CII-specific changes in
cytokine profile in DT-treated compared to PBS-
treated wild-type mice (Additional file 2: Figure S2d).
Intracellular analysis for Th17 and FoxP3
+ T cells also
showed no differences (Additional file 2: Figure S2e).
Taken together, these data suggests a regulatory role
for mast cells in the early stages of CIA, when the im-
mune response is established, that precedes the onset of
clinical symptoms.
Discussion
Mast cells are well known for their contribution to aller-
gies and hypersensitivity [32]. They have also been impli-
cated in autoimmune diseases such as RA. Increased
mast cell numbers in the synovium were observed, as
well as elevated levels of mast cell activation markers,
such as tryptase and chymase, in synovial fluid [33].
Both in RA as well as in experimental arthritis models
the possible pathogenic role of mast cells is still under
debate. Several studies have been performed in mice
with mutations in the gene encoding for the c-Kit recep-
tor causing mast cell deficiency. c-Kit signaling, however,
is not only essential in mast cell development and sur-
vival but also affects many other hematopoietic lineages
like stem cells, innate lymphoid cells, neutrophils, and
nonhematopoietic cells such as melanocytes and germ
Fig. 4 Preclinical FcεRIβ+ cell depletion influences systemic cytokine profile and peripheral leukocytes subsets. a Serum levels of IL-6, IL-17, IFN-γ,
and IL-10 were quantified in serum of PBS- and DT-treated RMB-DBA/1 mice.(n = 15/group). b FACS analysis of the blood compartment for peripheral
leukocytes (n = 15/group). (**p < 0.01 ***p < 0.001). A representative example of two independent experiments is depicted. DT diphtheria
toxin, IFN interferon, IL interleukin, PBS phosphate-buffered saline, TNF-α tumor necrosis factor
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cells [34]. To circumvent the side effects of c-Kit muta-
tions, mice have been generated with a normal Kit sig-
naling pathway, in which mast cell deficiency is more
selective. Induction of arthritis by K/BxN serum transfer
in, for example, Cpa3-cre mice induced clinical arthritis,
which was comparable to mast cell-competent mice
[15]. Similarly, pharmacological stabilization of mast
cells in the clinical phase of CIA with the drug nedocro-
mil was unable to reduce the clinical score of DBA/1
mice compared to placebo-treated mice [35]. In contrast,
it was shown that the mast cell inducible knock-out
Mcpt5-cre iDTr mouse developed reduced levels of
collagen-induced arthritis, when mast cells were de-
pleted before induction of arthritis (i.e., before the first
immunization with CII) [21]. This depletion reduced
both the number of immune cells in the draining lymph
nodes and the amount of secreted inflammatory cyto-
kines in response to collagen II. DT treatment of these
Mcpt5-Cre iDTR mice results, however, in a reduction
in the number of connective tissue-type mast cells
(CTMC) only, not that of mucosal mast cells (MMC)
[36]. Interestingly, it is reported that mast cells in the in-
flamed synovium express less Mcpt5 compared to
perivascular mast cells [37], indicating a microenviron-
mental regulation of the mast cell phenotype inside the
synovium.
In the current study, we sought to investigate the contri-
bution of mast cells to the different stages of collagen-
induced arthritis, when the first immunization was done
in a mast cell-competent mouse to exclude the possibility
that the absence of mast cells affected the immunization
efficiency. We have crossed the RMB mouse on a C57BL/
6 background [22] with the DBA/1 mouse, thus generat-
ing the RMB-DBA/1 mouse, in which mast cells can be
selectively depleted while being highly susceptible to the
induction of CIA. We observed an >90 % incidence of
CIA in these RMB-DBA/1 mice, which is comparable to
the incidence in homozygous DBA/1 mice [20, 28], ren-
dering this a valuable mouse model to study mast cells in
CIA. Using this model, we were able to deplete fully
FcεRIβ+ cells (mast cells and basophils) at any phase of
disease. Activated mast cells secrete a wide range of prote-
ases and lipid mediators, but also of a number of cytokines
and chemokines, such as IL-6, IL-8 and CCL2. These cy-
tokines are described to influence both the adaptive im-
mune response and attraction of leukocytes to the side of
Fig. 5 Altered CD4+T cell phenotype in spleen and enhanced anti-inflammatory response toward collagen type II of splenocytes from FcεRIβ+
cell-depleted mice. a Splenocytes from PBS- and DT-injected RMB-DBA/1 mice were stained intracellularly for IL-17 after stimulation with
anti-CD3/28 (n = 15/group). b Splenocytes from PBS- and DT-injected RMB-DBA/1 mice were stained intracellularly for FoxP3. (n = 15/group). c Cytokine
release of splenocytes from PBS- or DT-injected RMB-DBA/1 mice after restimulation with either αCD3/28 or collagen type II (n = 15/group). (*p< 0.05). A
representative example of two independent experiments is depicted. DT diphtheria toxin, IFN interferon, IL interleukin, PBS phosphate-buffered saline,
TNF-α tumor necrosis factor
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inflammation [38]. Activated basophils are well known for
their capacity to secrete cytokines such as IL-4, IL-13,
which influence the T cell skewing toward a Th2 response
[39]. The repopulation kinetics of mast cells and basophils
after the last DT injection differs. While a complete recov-
ery of basophils is observed within 12 days after the last
DT injection, mast cells depletion lasts for the entire dur-
ation of the experiment. Therefore, it is highly likely that
the majority of the observed effects in this study are due
to mast cell depletion rather than the absence of baso-
phils. Nonetheless, we cannot exclude that basophils do
contribute to the immune response in this relatively short
period.
Our data suggest that mast cells are involved during
the initiation of arthritis and that their role is limited
after the first appearance of clinical symptoms, at least
in the CIA model. During the preclinical phase of CIA,
we and other have detected mast cell-specific activators
like collagen-specific IgE antibodies [40]. IgE-mediated
activation leads to the degranulation of mast cells result-
ing in the release of immune-modulating mediators. Fur-
thermore, a peak of degranulated (activated) mast cells
in the knee and digits was recently shown around the
booster injection in the CIA model [35]. This may sug-
gests that mast cells contribute to the early development
of an immune response in experimental arthritis. For ex-
ample, it has been shown that mast cells can contribute
to T cell priming through the release of TNF-α in the
draining lymph nodes leading to expansion of the tissue
[41]. Our ex vivo experiments indicated that mast cell
depletion in the preclinical phase resulted in an altered
T cell skewing, as we detected a marked reduction in IL-
17 and an increase in IL-10 production by splenocytes of
mast cell-depleted mice after stimulation with collagen
type II.
IL-6 is a key cytokine for the development and main-
tenance of Th17 cells in mice [42]. This cytokine can be
produced by various innate immune cells including mast
cells. IgE-mediated mast cell activation results in high
secretion of both IL-6, which is a potent promoter of
Th17 cell induction, and TNF-α, which can drive the
hypertrophy of the draining lymph nodes and the re-
cruitment of naïve CD4+ T cells into the lymph node
[41, 43]. In the current study, we detected collagen type
II-specific IgE antibodies, indicating the presence of a
CIA-specific mast cell activator. Mast cell-derived cyto-
kines such as IL-6 may influence T cell skewing or other
cellular interactions in the lymph node. The importance
of IL-6 in CIA has been demonstrated by blocking IL-6,
which reduces the severity of arthritis [44]. Clinical trials
in human RA with anti-IL6R (tocilizumab) have demon-
strated that blockade of IL-6 has therapeutic efficacy in
(early) RA patients [45]. In this study, we observed lower
levels of serum IL-6 in mast cell-depleted mice. This
reduction of IL-6 coincided with an altered T cell skew-
ing toward a more anti-inflammatory T cell phenotype.
Th17 cells have been implicated to play a role in CIA
by driving arthritis progression through, e.g., osteoclast
activation [44, 46]. Furthermore, it was shown that anti-
IL-17 treatment significantly reduced arthritis develop-
ment and severity in mice [46, 47]. Also in human RA,
IL-17 and IL-17+ cells have been reported to contribute
to RA progression. For example, elevated levels of IL-
17A can be detected in serum and synovial fluid of RA
patients [48], and IL-17+ cells can be present in synovial
tissue from RA patients. Interestingly, the most abun-
dant IL-17+ cell type in RA synovium were mast cells
[49]. Flow cytometry analysis of stimulated splenocytes
from mast cell-depleted mice showed a decrease in CD4
+ IL-17+ T cells and an increase in regulatory CD4+
FoxP3+ T cells. Furthermore, we detected elevated levels
of IL-10 in the supernatant of splenocytes after stimula-
tion with collagen II. In CIA, the protective role of IL-10
has been previously been shown by both systemic treat-
ment of IL-10 and in mice deficient for IL-10 [50–52].
Whether mast cells pay a role in the established phase
of RA is not known. However, it is known that they can
represent an abundant cell type in the inflamed synovium
[6, 7]. Likewise, it has been shown that the autoimmune
response coinciding with seropositive RA represents fea-
tures of an active ongoing immune response [53]. This
could also include the mast cell, which might play a role
in the modulation of this response either in the inflamed
synovial tissue or in the draining lymph node by the secre-
tion of cytokines [54]. Whether mast cells also mediate
other effects in RA is not known. However, the presence
of mast cells in both human RA and mouse experimental
arthritis suggests a contributing part. Although CIA shows
many similarities with human RA, it also differs in terms
of progression of arthritis. Since human RA is less pro-
gressive and shows also flares of arthritis, it could be that
mast cells here do play a role.
The role of mast cells has also been investigated in
other models of autoimmune diseases, such as experi-
mental autoimmune encephalomyelitis (EAE). Similar to
the results obtained from experimental arthritis studies,
data from EAE studies also vary depending on the mast
cell-deficient mouse strain used [55]. As circulating IL-6
and IL-17 levels were reduced in this study, it would be
of interest to determine mast cell-dependent effects on
EAE with our RMB mouse, since it has been shown that
IL-6 and IL-17 are important in EAE development [56].
Taken together, the selective absence of mast cells can
have different consequences in different diseases, de-
pending on the time of mast cell depletion, the mouse
strain used, and/or the experimental conditions used. As
disease manifestation varies between individual patients,
it is conceivable that the contribution of mast cells to
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disease development can vary between individuals,
between disease stages, as well as between different
diseases.
Conclusions
In conclusion, we show that depletion of mast cells dur-
ing the initiation of experimental arthritis decreases dis-
ease severity, while depletion of mast cells in established
disease had no effect. Depletion of mast cells in the pre-
clinical phase of CIA is associated with a more anti-
inflammatory T cell response, suggesting that mast cells
could play a role in the regulation of the adaptive im-
mune response in early arthritis.
Additional files
Additional file 1: Figure S1. Study outline of performed arthritis
experiments in RMB-DBA/1 mice. (A) Mast cell depletion in clinical phase
of CIA. (B) Collagen antibody-induced arthritis in mast cell-depleted RMB-
DBA/1 mice. (C) Mast cell depletion in preclinical phase. (DT diphtheria
toxin, CFA complete Freund’s adjuvant, CII collagen type II, IFA incomplete
Freund’s adjuvant). (TIF 6909 kb)
Additional file 2: Figure S2. DT treatment in wild-type control animals.
(A) Progression of CIA was monitored by clinical scoring of C57Bl/6-DBA/
1 mice injected with either PBS or DT. (B) Serum levels of IL-6, IL-17, IFN-γ
and IL-10 were quantified in serum of PBS and DT-treated C57Bl/6-DBA/1
mice. (C) FACS analysis of the blood compartment for peripheral leuko-
cytes in PBS- and DT-treated C57Bl/6-DBA/1 mice. (D) Cytokine release of
splenocytes from PBS- or DT-injected C57Bl/6-DBA/1 mice after restimula-
tion with either αCD3/28 or collagen type II, or unstimulated medium
control (n = 15/group). (E) Splenocytes from PBS- and DT-injected C57Bl/
6-DBA/1 mice were stained intracellularly for IL-17 after stimulation with
anti-CD3/28 (n = 15/group). Splenocytes from PBS- and DT-injected
C57Bl/6-DBA/1 mice were stained intracellularly for FoxP3. (**p < 0.01,
****p < 0.001) All graphs n = 15/group). (TIF 7185 kb)
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